Tag : CHEMOTHERAPY

CONFERENCE UPDATE

Nivolumab + chemotherapy improves long-term survival outcomes in resectable NSCLC: Final OS analysis from the CheckMate 816 trial
In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.
CONFERENCE UPDATE

Development of a TR-TRM model as a risk prediction tool for severe toxicities in elderly cancer patients on systemic treatment
Older cancer patients face an elevated risk of severe treatment-related toxicities (TRT), partly due to age-related physiological changes and comorbidities. However, existing tools for predicting chemotherapy toxicity have limitations in both development and practical use.
CONFERENCE UPDATE

Liver transplantation + chemotherapy improves survival rates for patients with unresectable colorectal liver metastases
Although liver resection is the best treatment for colorectal liver metastases (CLM), only 20% of cases are initially resectable, while others require conversion chemotherapy (CTx) before undergoing secondary resection after downsizing.